TY - JOUR
T1 - Suppression of immune responses by herpes virus type 2-transformed murine tumor cells
AU - Prabhu Das, Mercy R.
AU - Gridley, Daila S.
AU - Kettering, James D.
N1 - Work done in our laboratories, using a murine model, indicates that suppression of host immune responses might be due to secretion of soluble factors ...
PY - 1991/9
Y1 - 1991/9
N2 - Work done in our laboratories, using a murine model, indicates that suppression of host immune responses might be due to secretion of soluble factors by tumor cells. The H238 cells (BALB/c embryonic fibroblasts transformed by UV-inactivated herpes simplex virus Type 2) exhibit progressive tumor growth with subsequent decrease in lymphoproliferation. To further study the suppressive effects of a tumor, H238 conditioned medium (CM) was tested for its ability to block murine and human mitogenic and allogeneic lymphocyte responses. PHA, Con A and LPS were used as mitogens. Lymphoproliferation, in the presence of increasing amounts of H238 CM, resulted in a greater degree of suppression of [3H]thymidine ([3H]Tdr) uptake, in both human and mouse systems. The kinetics of proliferation in the presence of concentrated H238 CM (cCM) showed that depression was evident regardless of the time of cCM addition, thereby affecting it at any stage of the cell cycle. Treatment of H238 cCM using acid (pH 2.3), base (pH 9.6), trypsin (100 μg/ml), heat (56°C, 100°C) and freeze-thawing, restored PHA-stimulated lymphoproliferation. Dialysis of H238 cCM showed that the molecular weight of the suppressor lies between 15 and 25 kDa. Northern blot analysis demonstrated the presence of a TGF-β transcript in H238 cells. Neutralization of the H238 cCM with monoclonal antibody to TGF-β resulted in complete abrogation of suppressive activity in spleen cell lymphoblastogenesis. These results suggest that TGF-β appears to be the main inhibitor of immune responses found in this HSV-2-induced murine tumor cell line. Such tumor-induced modulations may contribute to the outcome of immunotherapy in the tumor-bearing host.
AB - Work done in our laboratories, using a murine model, indicates that suppression of host immune responses might be due to secretion of soluble factors by tumor cells. The H238 cells (BALB/c embryonic fibroblasts transformed by UV-inactivated herpes simplex virus Type 2) exhibit progressive tumor growth with subsequent decrease in lymphoproliferation. To further study the suppressive effects of a tumor, H238 conditioned medium (CM) was tested for its ability to block murine and human mitogenic and allogeneic lymphocyte responses. PHA, Con A and LPS were used as mitogens. Lymphoproliferation, in the presence of increasing amounts of H238 CM, resulted in a greater degree of suppression of [3H]thymidine ([3H]Tdr) uptake, in both human and mouse systems. The kinetics of proliferation in the presence of concentrated H238 CM (cCM) showed that depression was evident regardless of the time of cCM addition, thereby affecting it at any stage of the cell cycle. Treatment of H238 cCM using acid (pH 2.3), base (pH 9.6), trypsin (100 μg/ml), heat (56°C, 100°C) and freeze-thawing, restored PHA-stimulated lymphoproliferation. Dialysis of H238 cCM showed that the molecular weight of the suppressor lies between 15 and 25 kDa. Northern blot analysis demonstrated the presence of a TGF-β transcript in H238 cells. Neutralization of the H238 cCM with monoclonal antibody to TGF-β resulted in complete abrogation of suppressive activity in spleen cell lymphoblastogenesis. These results suggest that TGF-β appears to be the main inhibitor of immune responses found in this HSV-2-induced murine tumor cell line. Such tumor-induced modulations may contribute to the outcome of immunotherapy in the tumor-bearing host.
KW - Cancer
KW - HSV-2-transformed fibroblasts
KW - Immunosuppression
KW - Transforming growth factor-β
UR - https://www.scopus.com/pages/publications/0025882845
UR - https://www.scopus.com/pages/publications/0025882845#tab=citedBy
U2 - 10.1016/0165-2478(91)90087-Q
DO - 10.1016/0165-2478(91)90087-Q
M3 - Article
C2 - 1660030
SN - 0165-2478
VL - 30
SP - 37
EP - 45
JO - Immunology Letters
JF - Immunology Letters
IS - 1
ER -